{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=46",
    "query": {
      "intervention": "control 2",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 22188,
    "total_pages": 2219,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T14:52:28.844Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04101422",
      "title": "Utilizing Augmented Reality as an Adjunct for Smoking Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Augmented Reality 1",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Augmented Reality 2",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Augmented Reality 3",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Augmented Reality 4",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2019-10-07",
      "completion_date": "2022-02-14",
      "has_results": true,
      "last_update_posted_date": "2023-05-22",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04101422"
    },
    {
      "nct_id": "NCT03847922",
      "title": "Nitrous Oxide for Analgesia During Office Urethral Bulking",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Stress Incontinence, Female"
      ],
      "interventions": [
        {
          "name": "Nitrous Oxide + Oxygen Gas (Product)",
          "type": "DRUG"
        },
        {
          "name": "lidocaine gel 2%",
          "type": "DRUG"
        },
        {
          "name": "Room air",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2019-02-15",
      "completion_date": "2020-07-23",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847922"
    },
    {
      "nct_id": "NCT02621931",
      "title": "Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1130,
      "start_date": "2016-03-22",
      "completion_date": "2017-04-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 179,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02621931"
    },
    {
      "nct_id": "NCT02614586",
      "title": "Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TAK-058",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "TAK-058 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-12",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-05-01",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614586"
    },
    {
      "nct_id": "NCT03996369",
      "title": "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Etrasimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 354,
      "start_date": "2020-09-15",
      "completion_date": "2021-12-07",
      "has_results": true,
      "last_update_posted_date": "2022-12-21",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 62,
      "location_summary": "Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03996369"
    },
    {
      "nct_id": "NCT05361941",
      "title": "Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Periprosthetic Joint Infections"
      ],
      "interventions": [
        {
          "name": "EP Granules with Tobramycin",
          "type": "DEVICE"
        },
        {
          "name": "empty voids",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Elute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2023-08-31",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Skokie, Illinois + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361941"
    },
    {
      "nct_id": "NCT06891066",
      "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1) Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "ULO",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-04-14",
      "completion_date": "2031-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891066"
    },
    {
      "nct_id": "NCT00004637",
      "title": "Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Vitamin E",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004637"
    },
    {
      "nct_id": "NCT02438345",
      "title": "PRO 140 for Human Immunodeficiency Virus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PRO 140",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Drexel University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 1,
      "location_summary": "Phildadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Phildadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438345"
    },
    {
      "nct_id": "NCT07144345",
      "title": "Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle containing excipients only (VEH) without active ingredient",
          "type": "OTHER"
        },
        {
          "name": "Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 160,
      "start_date": "2025-11-19",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-31T14:52:28.844Z",
      "location_count": 10,
      "location_summary": "Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "New Brighton",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07144345"
    }
  ]
}